Takeda Pharmaceutical will present four studies highlighting scientific updates on Adcetris (brentuximab vedotin) in Hodgkin’s lymphoma at the upcoming 10th International Symposium on Hodgkin Lymphoma (ISHL) Oct. 22-25 in Cologne, Germany. The company is the Jubilee sponsor of this year’s symposium.
“The data to be presented at this year’s ISHL are a proof point of the excellent progress we have made in furthering the clinical program of brentuximab vedotin,” Dr. Dirk Huebner, MD, executive medical director of the Oncology Therapeutic Area Unit at Takeda, said in a press release.
“Through our robust ongoing clinical investigation program, we have continued to see [the] benefit of brentuximab vedotin, particularly in patients with Hodgkin lymphoma or other CD30-positive malignancies who would typically face a poor prognosis. We remain committed to bringing this important therapy to all patients who might benefit from it.”
Hodgkin’s lymphoma is distinguished from other types of lymphoma by the presence of Reed-Sternberg cells, which have the CD30 protein at their cell surface.
The current gold standard treatment for chemosensitive relapsed/refractory Hodgkin’s lymphoma is high-dose salvage chemotherapy plus autologous stem cell transplant (ASCT), but this approach is capable of treating about half of Hodgkin’s lymphoma cases.
Adcetris is an antibody-drug conjugate that combines an anti-CD30 antibody linked to a microtubule-disrupting agent, monomethyl auristatin E (MMAE). The drug has been shown to reach a response rate of 75 percent in patients with relapsed or refractory Hodgkin’s lymphoma.
For the first time, Takeda will present the clinical results of a Phase 4 clinical trial (NCT01909934) that evaluated the effectiveness and safety of Adcetris in patients with relapsed or refractory Hodgkin’s lymphoma who are ineligible for stem cell transplants or multi-agent chemotherapy. The study is currently recruiting patients in several European countries.
The other three presentations will be focused on real-world evidence of Adcetris. The following abstracts will be presented during poster sessions:
- “Single-arm study of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma (RRHL) who are ineligible for stem cell transplant (SCT) or multi-agent chemotherapy.”
- “Real-World Effectiveness of Brentuximab Vedotin (BV) vs. Other Treatments in Patients with Relapsed/Refractory Hodgkin Lymphoma (RRHL) Post Autologous Stem-Cell Transplantation (ASCT).””
- “Brentuximab vedotin (BV) in Patients who are Ineligible for Autologous Stem Cell Transplant (ASCT) with Relapsed or Refractory Hodgkin Lymphoma (rrHL): A UK and Germany Retrospective Study.”
- “Risk Factors (RFs) for Relapse in Patients with Relapsed or Refractory Hodgkin Lymphoma (rrHL) after Autologous Stem Cell Transplant (ASCT): A Real-World Analysis in Germany and the United Kingdom (UK).”
In 2012, Adcetris was approved in Europe for the treatment of adults with relapsed or refractory CD30-positive Hodgkin’s lymphoma following ASCT or at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option, and for relapsed or refractory systemic anaplastic large cell lymphoma.
In June, the approval was extended to treat adult patients with CD30-positive Hodgkin’s lymphoma who are at high risk of disease progression or relapse following ASCT.